Nutriband Inc. Reports Record Third Quarter Revenue and Advances AVERSAâ„¢ Fentanyl Development Plans
Nutriband Inc. reports record Q3 revenue and advances AVERSA Fentanyl development, targeting NDA submission in 2025.Quiver AI SummaryNutriband Inc. announced its third-quarter financial results for 2024,...
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSAâ„¢ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology  Nutriband...